Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in  engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.

    After working for 10 years in Paris at Gustave Roussy institute, Sanofi-Aventis, INSERM Unit 535 and Necker Hospital, he passed in 2009 the national health and medical research institute (INSERM) competitive examination for a research engineer permanent contract.  

    Then, he worked in an epidemiology unit at the Cardiovascular Research Center of Paris (PARCC) located in Georges Pompidou European hospital. In 2013, he decided to join the  Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon with his engineer permanent contract. He teaches statistics, data Analysis and methodology in master’s degree and in medical school. 

    Since 2017, he is the head of the “Epidemilogy and Biostatistics” UMQVC’s module and the head of the GERCOR statistical team (INCAS’s labelled data center). He is also a member of the ARCAD foundation and of the HaliodDx’s Scientific Advisory Boards.


Research thematic:

  • Methodology in prognostic research and risk stratification
  • Development and improvement of prognostic and/or predictive tools at population and individual level. 

Main areas of expertise:  

  • Statistics and epidemiology
  • Clinical trial design ans analysis
  • Clinical research
  • Genetic epidemiology (linkage and association analyses)
  • Oncology
  • Solid transplantation (kidney and heart)
  • Cardiology

Main ongoing external collaborations :

  • GERCOR (Multidisciplinary Group in Oncology)
  • Fondation ARCAD (Aide et Recherche en Cancérologie Digestive)
  • AGEO (Association des Gastro-Entérologues Oncologues)
  • FRENCH (Fédération de Recherche EN Chirurgie)

Tools online

  • Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score 
  • Prognostic Nomogram and Score to Predict Overall Survival in Second Line Chemotherapy for Advanced Pancreatic Cancer: The PROSCAP score 

Principaux articles

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Nom de la revue : JNCI J Natl Cancer Inst

sample

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : New England Journal of Medicine

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

sample

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : BMJ

Derniers articles

sample

AbstractAims: The addition of docetaxel to cisplatin and 5-fluorouracil (DCF) has shown promising efficacy in...

Posté par : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Ther Adv Med Oncol

sample

AbstractBackground: Although no data have been reported beyond second-line therapy, aflibercept is approved in this...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Clin Colorectal Cancer

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Nom de la revue : Lancet Oncol

sample

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posté par : Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Dr. Guillaume MOUILLET
Nom de la revue : Bull Cancer

sample

AbstractBACKGROUND:Despite the critical roles of Th1-polarised CD4+ T cells in cancer immunosurveillance, the...

Posté par : Dr. Dewi VERNEREY
Nom de la revue : Br J Cancer.

sample

BACKGROUND:RAS mutations are currently sought for in tumor samples, which takes a median of almost 3 weeks in western...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN, Mme. Aurélia MEURISSE
Nom de la revue : Ann Oncol

sample

AbstractPurpose: Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clin Cancer Res .

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JCO

sample

Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Guillaume MOUILLET
Nom de la revue : JNCI Journal of the National Cancer Institure

sample

AbstractBACKGROUND:Recurrence patterns in stage III colon cancer (CC) patients according to molecular markers remain...

Posté par : , Dr. Dewi VERNEREY
Nom de la revue : Ann Surg Oncol.

Dernières actualités

Derniers outils

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posté par : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN,

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

Posté par : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Currently, the management of advanced pancreatic cancer patients is complex in second-line chemotherapy according to the...

Posté par : Dr. Angélique VIENOT, Dr. Dewi VERNEREY

2015-2022 © Copyright - UMQVC.org

Website by Pearlweb